Skip to main content
Clinical Trials/NL-OMON44790
NL-OMON44790
Completed
Not Applicable

The role of the tumor microenvironment of pancreatic cancer to predict treatment outcome - Microenvironment of pancreatic cancer (MIPA)

Academisch Medisch Centrum0 sites95 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
pancreatic cancer
Sponsor
Academisch Medisch Centrum
Enrollment
95
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • \* Patients with pancreatic tumors, with histological or cytological proof of adenocarcinoma or a high suspicion on CT imaging.
  • \* Tumor size \* 1cm.
  • \* WHO\-performance score 0\-2\.
  • \* Scheduled for surgery or neo\-adjuvant chemotherapy/radiation followed by surgery. For the reproducibility part of the study, patients who will not undergo surgery, may be included, too.
  • \* Written informed consent.

Exclusion Criteria

  • \* Any psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol.
  • \* Contra\-indications for MR scanning, including patients with a pacemaker, cochlear implant or neurostimulator; patients with non\-MR compatible metallic implants in their eye, spine, thorax or abdomen; or a non\-MR compatible aneurysm clip in their brain; patients with severe claustrophobia.
  • \* Renal failure (GFR \< 30 ml/min) hampering safe administration of Gadolinium containing MR contrast agent.
  • \* For the reproducibility part of the protocol: surgery, radiation and/or chemotherapy foreseen within the timeframe needed for MR scanning.

Outcomes

Primary Outcomes

Not specified

Similar Trials